PerioTrap Pharmaceuticals GmbH
Weinbergweg 22, 06120 Halle (Saale)
Dr. James Belcher, December 2, 2025
Many toothpastes and mouthwashes promise to "kill 99% of all bacteria." Sounds good—but it isn't necessarily true. Your mouth is an ecosystem, and killing everything also destroys what protects it. Learn here why selective blockage is the future of oral care.
Microbiome modulation refers to an approach in oral care that doesn't "wipe out everything" but intervenes in a targeted way . Your mouth is home to over 700 different types of bacteria. Many of these are beneficial – they protect you from pathogens and strengthen your gums (Baker et al., 2024).
Conventional products like strong mouthwashes kill all bacteria indiscriminately . This disrupts the balance – experts refer to this as dysbiosis . As a result, harmful germs can recolonize more quickly, increasing the risk of inflammation (Koromantzos et al., 2025).
A stable oral microbiome acts like a natural protective shield . If it becomes unbalanced, gingivitis and periodontitis can result. Studies show that these local inflammations may be linked to diseases such as diabetes, cardiovascular disease , and possibly also Alzheimer's disease (Hajishengalis et al., 2021).
The future of dentistry therefore lies in combating pathogens such as Porphyromonas gingivalis to block them in a targeted manner – and simply let the good bacteria fulfill their protective function (Taudte et al. 2021; Eick et al., 2025).

PerioTrap researchers have developed a molecule called S-0636 that acts as a so-called pathoblocker . It does not kill P. gingivalis, but rather disables its disease-causing mechanisms – for example, the production of aggressive enzymes that attack tissue (Taudte et al., 2025).
This means: blockage of pathogenic germs and no harm to beneficial bacteria . In laboratory studies, biofilm mass could be reduced by up to 25% (Eick et al., 2025).
Baker JL, Mark Welch JL, Kauffman KM, McLean JS, He X. The Oral Microbiome: Diversity, Biogeography and Human Health. Nature Reviews Microbiology. 2024.
Eick S, Taudte N, Ramsbeck D, Magdon A, Sculean A, Potempa J, Buchholz M. Effect of a bacterial glutaminyl cyclase inhibitor on multi-species biofilms. Frontiers in Oral Health. 2025;6:1716625. doi:10.3389/froh.2025.1716625.
Hajishengallis G, Chavakis T. Local and Systemic Mechanisms Linking Periodontal Disease and Inflammatory Comorbidities. Nature Reviews Immunology. 2021.
James P, Worthington HV, Parnell C, et al. Chlorhexidine Mouthrinse as an Adjunctive Treatment for Gingival Health. The Cochrane Database of Systematic Reviews. 2017.
Koromantzos PA, Bobetsis YA, Giota C, et al. Effect of Adjunctive Use of Commercial Daily Mouthwashes on Periodontal Health: An Umbrella Review. Journal of Clinical Periodontology. 2025. doi:10.1111/jcpe.70061.
Tartaglia GM, Kumar S, Fornari CD, Corti E, Connelly ST. Mouthwashes in the 21 Century: A Narrative Review About Active Molecules and Effectiveness on the Periodontal Outcomes. Expert Opinion on Drug Delivery. 2017;14(8):973–982. doi:10.1080/17425247.2017.1260118.
Taudte N, et al. Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis. J Biol Chem. 2021;296:100263.
Taudte N, et al. Novel small molecule targeting PgQC reduces Porphyromonas gingivalis virulence. bioRxiv. 2025.09.30.679452. doi:10.1101/2025.09.30.679452. This article is a preprint and has not been certified by peer review.
Zeng Y, Lin D, Chen A, Ning Y, Li X. Periodontal Treatment to Improve General Health and Manage Systemic Diseases. Advances in Experimental Medicine and Biology. 2025.